• image

    the Phase 3 trial DIAGNODE-3

    and other ongoing trials

    Read More
  • image

    Developing precision therapies

    for type 1 diabetes

    VIDEO
  • image

    Intralymphatic immunotherapy

    with Diamyd®

    VIDEO

Press Releases 

Events & Mediawatch 

 February 19, 2025   Sweden

Events & Mediawatch 

 January 29, 2025   Sweden

Events & Mediawatch 

 January 15, 2025   Sweden
image

Events & Mediawatch 

 November 18, 2024   USA

Events & Mediawatch 

 November 15, 2024   Sweden

Company Presentation

 January 31, 2025
Download PDF

With full speed ahead, we continue advancing Diamyd®— our precision immunotherapy for Type 1 Diabetes — toward an FDA supported Phase-3 Study early read-out, that may be followed by an application for an accelerated market approval.

image Ulf Hannelius
President and CEO, Diamyd Medical AB
CEO Comments, Quarterly report 1, 24/25

Calendar

 Dates for financial information and other events
February 25 − February 27, 2025
8th Antigen-Specific Immune Tolerance Summit
March 5, 2025
Life Science-dagen 2025
March 13, 2025
Carnegie Healthcare Seminar 2025
March 19 − March 22, 2025
ATTD 2025
April 9, 2025
Quarterly Report 2
Quarterly Report 2 2024/2025
June 25, 2025
Quarterly Report 3
Quarterly Report 3 2024/2025
October 8, 2025
Year-end Report
Year-end Report 2024/2025

The Story of Diamyd Medical

The company founder Anders Essen-Möller reveals the story behind the company's founding and his mission to stop Type 1 Diabetes in its tracks. The film also features board member Karin Hehenberger, shedding light on the patient’s perspective, and board member Dr. Mark Atkinson speaking of the importance of the enzyme GAD in Type 1 Diabetes.

“ If it was not for the hundreds of clinical sites and their personnel, investigators, patients, investors, not to mention the fantastic entrepreneurial, yet diligent, Diamyd team - this current transformational precision therapy for autoimmune diabetes based on genetics, should probably still remain undiscovered.
How can I thank you all ? "

- Anders Essen-Möller, Chairman of the Board

Manufacturing of GAD65 in Umeå

Image
A facility for manufacturing of biological products is being set up in Umeå, the Capital of Västerbotten County in Sweden.
Read More

THE COMPANY

Diamyd Medical develops therapies for Type 1 Diabetes
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)


Read More

Order GAD for preclinical research

ORDER

Annual Report

  December 3, 2024
Annual Report cover image
Download

Contact Us

Diamyd Medical AB (publ)
Box 7349, SE-103 90 Stockholm
Visiting addresses:
Kungsgatan 29, SE-111 56 Stockholm
+46 8 661 00 26
Umeå:
Formvägen 7B, SE-906 21 Umeå

Subscribe

Follow Us

  ©
GAD PRODUCTS
Order GAD for preclinical research